News: Hospira Inc (HSP.N)

HSP.N on New York Stock Exchange

87.95USD
4 Mar 2015
Change (% chg)

$0.24 (+0.27%)
Prev Close
$87.71
Open
$87.66
Day's High
$87.96
Day's Low
$87.66
Volume
465,993
Avg. Vol
396,089
52-wk High
$87.96
52-wk Low
$40.44

Search Stocks
Select another date:

Tue, Mar 3 2015

MOVES-Guggenheim hires healthcare bankers from JPMorgan, BofA - WSJ

March 3 - Guggenheim Partners has hired Jeff Hoffman and Joseph Kohls as senior managing directors to bolster its healthcare investment banking team, the Wall Street Journal reported.

UPDATE 1-Biosimilar copies of blockbuster drug launch in major EU markets

* Biosimilars expected to disrupt market for biotech medicines (Adds detail on price discount, paragraph 7)

Biosimilar copies of blockbuster drug launch in major EU markets

* Biosimilars expected to disrupt market for biotech medicines

RPT-Pfizer's Hospira deal bets on price spike for specialty generics

NEW YORK, Feb 5 - Pfizer Inc's $15 billion deal to buy Hospira Inc will allow the largest U.S. drugmaker to benefit from specialty generic medicines that are commanding far higher prices than traditional off-patent pills, industry investors and analysts said.

India Morning Call-Global Markets

NEW YORK - U.S. stocks climbed on Thursday as energy shares bounced with oil prices, while news Pfizer Inc would buy Hospira Inc in a massive deal further boosted the market.

Pfizer's Hospira deal bets on price spike for specialty generics

NEW YORK - Pfizer Inc's $15 billion deal to buy Hospira Inc will allow the largest U.S. drugmaker to benefit from specialty generic medicines that are commanding far higher prices than traditional off-patent pills, industry investors and analysts said.

Pfizer's Hospira deal bets on price spike for specialty generics

NEW YORK, Feb 5 - Pfizer Inc's $15 billion deal to buy Hospira Inc will allow the largest U.S. drugmaker to benefit from specialty generic medicines that are commanding far higher prices than traditional off-patent pills, industry investors and analysts said.

Wall St climbs with energy rebound, Pfizer deal

NEW YORK - U.S. stocks climbed on Thursday as energy shares bounced with oil prices, while news Pfizer would buy Hospira in a massive deal further boosted the market. | Video

US STOCKS-Wall St climbs with energy rebound, Pfizer deal

* Indexes up: Dow 1.2 pct, S&P 1 pct, Nasdaq 1 pct (Updates close with latest volume, LinkedIn, Twitter up after the bell)

US STOCKS-Wall St climbs with energy rebound, Pfizer deal

* Indexes up: Dow 1.2 pct, S&P 1 pct, Nasdaq 1 pct (Updates to close)

Select another date:
Search Stocks